TX-MARY-KAY
20.6.2024 18:04:28 CEST | Business Wire | Press release
Mary Kay Inc., a global leader in skin care innovation, recently revealed the results of two breakthrough research studies: first, an antioxidant treatment that can diminish the visible effects of pollution and aging on human skin; and second, a focus on the applications of computational tools to accurately predict the safety and potential reactions of human skin to various cosmetic ingredients. These findings were shared by Mary Kay scientists at the 2024 Society of Investigative Dermatology (SID) meeting in Dallas, Texas. The company was a silver-level sponsor of the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620935246/en/
Mary Kay Inc. recently revealed the results of two breakthrough research studies at the 2024 Society of Investigative Dermatology. (Photo: Mary Kay Inc.)
“Mary Kay scientists are at the forefront of skin care research, and we’re pleased to share our latest findings with the broader scientific community,” said Dr. Lucy Gildea, Chief Innovation Officer, Product & Science at Mary Kay. The ongoing partnership with the Society of Investigative Dermatology underscores Mary Kay’s dedication to advancing skincare science. By maintaining collaborative efforts, the company remains steadfast in its commitment to making significant breakthroughs in the field of dermatology, ultimately providing consumers with safer and more effective skincare solutions.
“Mary Kay's enduring commitment to research and development aligns perfectly with our goals at the Society for Investigative Dermatology," said Dr. Rebecca Minnillo, Chief Program, Communications and Development Officer at SID. "Our sustained partnership enables us to explore new frontiers in dermatological science, bringing us closer to breakthroughs that can transform skin care and treatment options.”
Mary Kay's research into the effects of air pollution on skin, conducted through multiple academic collaborations since 2016, revealed that an antioxidant blend of resveratrol, niacinamide, and oligopeptide-1 protects natural skin surface lipids from oxidative damage caused by particulate matter (PM) and UV radiation, both alone and combined. Additionally, this blend has been found to prevent free radical formation induced by blue light, demonstrating its potential in mitigating the detrimental effects of multiple environmental stressors on the skin.
Furthermore, Mary Kay is leveraging computational toxicology tools to enhance ingredient safety assessment of cosmetic and personal care ingredients. This innovative approach involves the use of advanced computational methods to predict the safety and potential toxicity of ingredients at an early stage, significantly reducing the need for extensive laboratory testing. Virtual screening allows for the early screening of compounds, ensuring only safe ingredients proceed in the development process. This method not only saves time and resources but also aligns with ethical and regulatory standards. By integrating these advanced tools, Mary Kay underscores its commitment to leveraging cutting-edge technology for product development, ensuring the highest standards of safety and efficacy for its consumers.
Mary Kay’s Dr. Gildea also hosted a compelling panel at SID, titled "Insights into the Effects of Pollution on Skin Health: Recent Discoveries & Emerging Perspectives,” comprising experts from varied fields of dermatology and molecular biology. Panelists included Dr. Thomas Haarmann-Stemmann, Group Leader at the Leibniz Research Institute for Environmental Medicine, who discussed the link between increased ambient temperature and skin aging. Dr. Elma Baron, Associate Professor of Dermatology at Case Western Reserve University, emphasized the significance of topical antioxidants in mitigating oxidative stress and improving skin health. Dr. Hong Sun, Assistant Professor at NYU Grossman School of Medicine, delved into molecular changes in skin cells exposed to environmental stressors, demonstrating the efficacy of antioxidant treatments in reversing gene expression changes associated with skin damage induced by UV and pollution exposure.
The sponsorship and findings presented at the 2024 SID meeting represent the latest efforts by Mary Kay to reinforce the brand’s long-standing commitment to advancing research and development in skin health and beauty. With over 1,600 patents for products, technologies, and packaging designs in its global portfolio, Mary Kay continues to lead the way in skincare innovation.
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620935246/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
